Overview
Tesamorelin is a synthetic analog of Growth Hormone-Releasing Hormone (GHRH), designed to stimulate the release of growth hormone in experimental models. Due to its stability and extended half-life compared to native GHRH, Tesamorelin has become a key subject of investigation in studies focused on metabolism, body composition, and endocrine signaling. This compound is provided exclusively for laboratory research use and is not intended for human consumption, medical, or diagnostic applications.

Research Focus
In preclinical and laboratory research, Tesamorelin has been examined in relation to:

• Growth hormone release – studying pituitary signaling and GHRH receptor activation.

• Metabolic regulation – investigating effects on energy balance and fat metabolism in experimental systems.

• Endocrine function – analyzing peptide interactions within the hypothalamic–pituitary axis.

• Body composition research – exploring its role in fat distribution and lean mass pathways in preclinical models.

Key Features

• Synthetic analog of GHRH

• Research-grade peptide with extended stability

• Supplied in lyophilized powder form

• Manufactured to high-purity standards

Specifications

• Synonyms: Egrifta (brand name), Tesamorelin Acetate

• Molecular Formula: C₂₂₁H₃₆₆N₇₂O₆₇S

• Molecular Weight: ~5135 Da

• Sequence: Modified GHRH(1-44) analog with stabilizing substitutions

• Purity: ≥98% (HPLC)

• Form: Lyophilized powder

• Storage: Store at –20°C; stable under recommended conditions

• Intended Use: Research use only. Not for human consumption, medical, or veterinary use.

Disclaimer
This material is supplied for laboratory research purposes only. It is not a drug, food, or cosmetic. The buyer assumes all responsibility for safe handling and lawful use.